Advanced prostate cancer research focuses on newer agents for mCRPC

April 17, 2014

Research in advanced prostate cancer is largely focused on newer agents for metastatic castration-resistant prostate cancer, including abiraterone acetate (ZYTIGA), enzalutamide (XTANDI), radium Ra 223 dichloride (Xofigo), and the immunotherapy sipuleucel-T (Provenge).

This articles is part of the State of Urology 2014

Dr. ThrasherResearch in advanced prostate cancer is largely focused on newer agents for metastatic castration-resistant prostate cancer (mCRPC), including abiraterone acetate (ZYTIGA), enzalutamide (XTANDI), radium Ra 223 dichloride (Xofigo), and the immunotherapy sipuleucel-T (Provenge).

“At this year’s annual meeting, we will hear more about optimal sequencing and use of the new drugs recently approved for mCRPC and get a glimpse at new agents being tested,” said J. Brantley Thrasher, MD, professor and chair of urology at the University of Kansas Medical Center, Kansas City.

Early-stage trials will examine the anti-cancer activity of VT-464, a small molecule CYP17A1 inhibitor, and Prostate Specific Membrane Antigen Antibody Drug Conjugate, a human antibody to PSMA.

Specifically, here are the can't-miss abstracts from this year's AUA annual meeting, as selected by Dr. Thrasher:

PD27-06: Simvastatin and Metformin: A Deadly Combination for Metastatic Castration-Resistant Prostate Cancer
Melissa Babcook

PD27-11: A Phase II, Randomized, Double-blind, Placebo-Controlled Trial of Methylphenidate for Reduction of Fatigue in Prostate Cancer Patients Receiving LHRH-Agonist Therapy
Patrick O. Richard

PD27-12: Biochemical efficacy of Enzalutamide in post-chemo mCRPC patients previously treated with Abiraterone
M. Andreas Røder

MP70-02: Treatment practice patterns in metastatic castration-resistant prostate cancer patients prior to receiving sipuleucel-T: Data from PROCEED
Matthew Cooperberg

MP70-05: Anti-cancer activity of the selective CYP17A1 inhibitor, VT-464, in pre-clinical models of castrate-resistant prostate cancer
Paul Toren

MP70-10: Further Characterization of the Effects of Prior or No Prior Docetaxel Therapy on CRPC Patients With Bone Metastases Receiving Ra-223 in the Phase 3 ALSYMPCA Trial
Neal Shore

MP70-13: Impact of Screening and treatment pattern on Racial and Ethnic Differences in Outcomes among Advanced Stage Prostate Cancer Patients
Sumedha Chhatre

MP70-18: Mortality in men with advanced prostate cancer may be reduced with radical treatment compared to androgen deprivation alone
Prasanna Sooriakumaran

MP70-20: A Phase 2 trial of Prostate Specific Membrane Antigen Antibody Drug Conjugate (PSMA ADC) in Taxane-Treated Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Daniel Petrylak

Subscribe to Urology Times to get monthly news from the leading news source for urologists.